Read Gene

Read Gene Market capitalization

The The market capitalization of Read Gene (RDG.WA) as of Nov 7, 2026 is 61.31 M PLN. In the previous year, The market capitalization was 61.31 M PLN — a change of 0.00% (lower).

Market capitalization

61.31 MPLN

YoY

0.00%

Last updated:

In 2025, Read Gene's market cap stood at 61.31 M PLN, a 0.00% increase from the 61.31 M PLN market cap in the previous year.

The Read Gene Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2018
61.31 M PLN
Jan 1, 2019
61.31 M PLN
Jan 1, 2020
61.31 M PLN
Jan 1, 2021
61.31 M PLN
Jan 1, 2022
61.31 M PLN
Jan 1, 2023
61.31 M PLN
Jan 1, 2024
61.31 M PLN
Jan 1, 2025
61.31 M PLN
The Read Gene Market capitalization history
YEARMarket capitalizationYoY
61.31 MPLN0.00%
61.31 MPLN0.00%
61.31 MPLN0.00%
61.31 MPLN0.00%
61.31 MPLN0.00%
61.31 MPLN0.00%
61.31 MPLN0.00%
61.31 MPLN0.00%
61.31 MPLN0.00%
61.31 MPLN0.00%
61.31 MPLN0.00%
61.31 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Read Gene's Market Capitalization

Read Gene's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Read Gene's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Read Gene's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Read Gene’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Read Gene stock

The market capitalization of Read Gene is 61.31 M PLN in 2025.

The market capitalization of Read Gene changed from 61.31 M PLN to 61.31 M PLN, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Read Gene since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's PLN, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' PLN varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Read Gene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Read Gene

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Read Gene